Biogen Idec Inc. said Tuesday that European uni0n regulators approved an injectable pen version of its multiple sclerosis drug Avonex.
The Avonex Pen is approved for patients who have experienced the first symptoms of MS, or who have the relapsing form of the disease. The pens are single-use pens with a dose that lasts one week. Biogen Idec said it will start making the pens available in Europe over the next few weeks.
Avonex is the Weston, Mass., company's biggest selling drug. Worldwide sales of Avonex totaled $2.52 billion in 2010.
Source: MedPage Today © 2011 Everyday Health, Inc. (07/06/11)